^
Association details:
| Biomarker: | KDR overexpression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Published date:
08/14/2023
Excerpt:
Both cohort 1 and 2 meets primary end point. In exploratory molecular analyses, B cell marker and tertiary lymphoid structure shows a positive associated with higher ORR in cohort 1, while a higher expression of PD-L1, VEGF Receptor 2 (KDR) and angiogenesis gene expression signatures are related with the higher efficiency in cohort 2....Camrelizumab plus apatinib combination effectiveness is associated with high expression of PD-L1, VEGF Receptor 2 and B-cell-related genes signatures. Camrelizumab plus apatinib shows promising efficacy with a measurable safety profile in RM-NPC patients.
DOI:
https://doi.org/10.1038/s41467-023-40402-x
Trial ID:
